EPS for Aurora Cannabis Inc. (ACB) Expected At $-0.04

September 8, 2018 - By Lisa Delgado

Analysts expect Aurora Cannabis Inc. (TSE:ACB) to report $-0.04 EPS on September, 25.They anticipate $0.03 EPS change or 300.00 % from last quarter’s $-0.01 EPS. After having $-0.05 EPS previously, Aurora Cannabis Inc.’s analysts see -20.00 % EPS growth. The stock decreased 0.85% or $0.07 during the last trading session, reaching $8.12. About 17.38M shares traded or 24.15% up from the average. Aurora Cannabis Inc. (TSE:ACB) has 0.00% since September 8, 2017 and is . It has underperformed by 12.57% the S&P500.

Aurora Cannabis Inc., together with its subsidiaries, produces and distributes medical marijuana products in Canada. The company has market cap of $7.73 billion. The company's products consist of dried cannabis and cannabis oil. It currently has negative earnings. It also operates as a pharmaceutical wholesaler and narcotics dealer of medical marijuana in Germany and the European Union; and produces and sells proprietary systems for the indoor cultivation of cannabis, organic microgreens, vegetables, and herbs.

More notable recent Aurora Cannabis Inc. (TSE:ACB) news were published by: Midasletter.com which released: “Aurora Cannabis Inc (TSE:ACB) CCO Cam Battley on Spin-out and Canopy Growth Corp – Constellation Brands Tie-up” on August 19, 2018, also Profitconfidential.com with their article: “Aurora Cannabis Stock: Why This Weed Play Could Easily Double” published on August 16, 2018, Midasletter.com published: “VIDEO: PI Financial Equity Analyst Reiterates Aurora Cannabis Inc (TSE:ACB) Buy Rating of $13” on August 15, 2018. More interesting news about Aurora Cannabis Inc. (TSE:ACB) were released by: Profitconfidential.com and their article: “Aurora Stock History” published on August 13, 2018 as well as Profitconfidential.com‘s news article titled: “Aurora Cannabis Stock” with publication date: September 04, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.